Form 4: Precigen COO Rutul R. Shah Granted 180,000 Restricted Stock Units

Precigen, Inc. Chief Operating Officer Rutul R. Shah was granted 180,000 restricted stock units (RSUs) as part of his compensation.

Summary

• Rutul R. Shah, the Chief Operating Officer of Precigen, Inc. (PGEN), acquired 180,000 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Precigen common stock.
• The transaction date for this acquisition was June 26, 2025.
• The RSUs will vest in two stages: 50% on May 23, 2026, and the remaining balance in equal monthly installments over the subsequent three years.
• Following this transaction, Mr. Shah beneficially owns 180,000 derivative securities in the form of RSUs.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a routine executive compensation event that aligns management's interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of restricted stock units to the Chief Operating Officer aligns management's long-term interests with those of the shareholders, as the value of the RSUs is tied to the company's stock performance.
• This RSU grant is a standard component of executive compensation, indicating a commitment to retaining key leadership.

Future Outlook

The vesting schedule for the Restricted Stock Units, extending through May 2026 and for three years thereafter, indicates a long-term retention strategy for the Chief Operating Officer and aligns his future compensation with the company's performance over this period.

Industry Context

The grant of Restricted Stock Units is a common form of equity-based compensation for executives in the biotechnology and pharmaceutical industries, designed to incentivize long-term performance and align management interests with shareholder value. This practice is standard across publicly traded companies, particularly in sectors requiring long-term strategic development.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a widely adopted practice across the biotech and broader corporate landscape, comparable to compensation structures at companies like Amgen, Gilead Sciences, or Moderna, which frequently utilize equity grants to attract and retain top talent.
• The vesting schedule, with a significant portion vesting after approximately one year and the remainder over a multi-year period, is typical for RSU grants, aiming to ensure executive retention and long-term commitment, similar to vesting schedules observed in companies of comparable size and industry.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of 180,000 Restricted Stock Units by Rutul R. Shah, the Chief Operating Officer, is a transaction between the company and a key executive, which is a form of related party transaction, specifically executive compensation.

Stakeholder Impact

• Shareholders: The RSU grant aims to align the Chief Operating Officer's interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: This type of executive compensation can set a precedent for performance-based incentives within the company, potentially influencing broader compensation strategies.

Next Steps

• The Restricted Stock Units will begin to vest, with 50% vesting on May 23, 2026.
• The remaining RSUs will vest in equal monthly installments over the three years following May 23, 2026.

Key Dates

Keywords

Precigen, PGEN, Rutul R. Shah, Restricted Stock Units, RSU, Equity Grant, Executive Compensation, SEC Form 4, Insider Transaction, Biotechnology, Pharmaceuticals